[1] Bast RC Jr,Hennessy B,Mills GB.The biology of ovarian cancer:New opportunities for translation[J].Nat Rev Cancer,2009,9(6):415-428. [2] Ozols RF,Bookman MA,Connolly DC,et al.Focus on epithelial ovarian cancer[J].Cancer Cell,2004,5(1):19-24. [3] Siegel R,Naishadham D,Jemal A.Cancer statistics,2013[J].CA Cancer J Clin,2013,63(1):11-30. [4] Monk BJ,Coleman RL.Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer:from platinum doublets to nonplatinum doublets.and adding antiangiogenesis compounds[J].Int J Gynecol Cancer,2009,19 (suppl 2):S63-S67. [5] Qin Y,Zhao X,Fang Y.PP242 synergizes with suberoylanilide hydroxamic acid to inhibit growth of ovarian cancer cells[J].Int J Gynecol Cancer,2014,24(8):1373-1380. [6] Marks PA,Breslow R.Dimethyl sulfoxide to vorinostat:development of this histone deacetylase inhibitor as an anticancer drug[J].Nat Biotechnol,2007,25(1):84-90. [7] Siegel D,Hussein M,Belani C,et al.Vorinostat in solid and hematologic malignancies[J].J Hematol Oncol,2009,2:31. [8] Bolden JE,Peart MJ, Johnstone RW.Anticancer activities of histone deacetylase inhibitors[J].Nat Rev Drug Discov,2006,5(9):769-784. [9] Olson DE,Sleiman SF,Bourassa MW,et al.Hydroxamate-based histone deacetylase inhibitors can protect neurons from oxidative stress via a histone deacetylase-independent catalase-like mechanism[J].Chem Biol,2015,22(4):439-445. [10] Slingerland M,Guchelaar HJ,Gelderblom H.Histone deacetylase inhibitors:an overview of the clinical studies in solid tumors[J].Anticancer Drugs,2014,25(2):140-149. [11] Emanuele S,Lauricella M,Tesoriere G.Histone deacetylase inhibitors:apoptotic effects and clinical implications(Review)[J].Int J Oncol,2008,33(4):637-646. [12] Grabarska A,Luszczki JJ,Nowosadzka E,et al.Histone deacetylase inhibitor SAHA as potential targeted therapy agent for larynx cancer cells[J].J Cancer,2017,8(1):19-28. [13] Fan M,Goodwin ME,Birrer MJ,et al.The c-Jun NH2-terminal protein kinase/AP-1 pathway is required for efficient apoptosis induced by vinblastine[J].Cancer Res,2001,61(11):4450-4458. [14] Liang B,Liu X,Liu Y,et al.Inhibition of autophagy sensitizes MDR-phenotype ovarian cancer SKVCR cells to chemotherapy[J].Biomed Pharmacother,2016,82:98-105. [15] Dietrich CS,Greenberg VL,DeSimone CP,et al.Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel-induced apoptosis in ovariancancer cell lines[J].Gynecol Oncol,2010,116(1):126-130. [16] Lee YJ,Won AJ,Lee J,et al.Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells[J].Int J Med Sci,2012,9(10):881-893. [17] Chen MY,Liao WS,Lu Z,et al.Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes,apoptosis,G2/M arrest and autophagy[J].Cancer,2011,117(19):4424-4438. [18] 王宝金,申爱荣,付喜玲,等.APTO-253 对紫杉醇或顺铂处理的卵巢癌 SKOV3 及 OVCAR3细胞凋亡及细胞周期的影响[J].郑州大学学报:医学版,2018, 53(1):75-79. |